Raising the Bar on Leadership for the Evolving CFO/Financial Executive

July 9, 2020 8:00 AM - 9:00 AM

Webinar, click "live-stream" button to view

Add to Calendar 7/9/2020 8:00:00 AM 7/9/2020 9:00:00 AM Raising the Bar on Leadership for the Evolving CFO/Financial Executive

Within the life science eco-system, the role of the CFO/financial executive continues to shift. CFOs and financial executives are assuming increasingly complex roles, from managing day-to-day responsibilities, to driving value creation across the business, to navigating the markets and volatility. As a ‘strategic partner’ to the CEO, CFOs/financial executives must master the art of balance and agility with appropriate skills, talents, experiences and support.


To start, below are five key characteristics that exemplify the evolving life science CFO/financial executive:

  • Holistic perspective encompassing the entire value chain
  • Insight and ability to communicate business drivers
  • Eye for the right kind of talent
  • Facility for cultural change
  • Integrity and interpersonal skills needed to pull all these together


How can you become a finance leader and recruit those who will support and succeed you? What should emerging finance leaders think about as they step into the CFO/financial executive role? Or for the seasoned executive who is taking on their 2nd or 3rd role, what should you keep in mind to ensure your ability to consistently lead with success?

Join us as we draw on the wisdom of our panelists to understand and discuss the art and expertise of today’s ‘successful, cross functional’ life science CFO/financial executive. Sponsored by the MassBio Business Development and Finance forum working group. MassBio makes every effort to accommodate our entire community at each of our events. Please let us know at least 3 days in advance of the event if you require special accommodations, such as captioning.

 Webinar, click "live-stream" button to view
BOD Member at Dyne Therapeutics
David Lubner is an accomplished financial leader in the biotech/life sciences space. He served as executive vice president and chief financial officer of Ra Pharmaceuticals, Inc., acquired by UCB, S.A. in April 2020, from 2016 until May 2020. Before joining Ra Pharma, David served as a member of the senior management team of Tetraphase Pharmaceuticals, Inc. and PharMetrics Inc., a leading patient-based pharmacy and medical claims data informatics company, which was acquired by IMS Health in 2015 and at ProScript, Inc., where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma, was discovered. He serves on the Board of Directors of Dyne Therapeutics Inc., focused on developing life-transforming therapies for inherited muscle diseases; Gemini Therapeutics Inc., a clinical stage precision medicine company developing innovative treatments for age-related macular degeneration (AMD) and, Ichnos Sciences. He previously served on the Board of Directors of Nightstar Therapeutics plc (NASDAQ: NITE), focused on the development of one-time retinal gene therapies for patients suffering from rare inherited retinal diseases acquired by Biogen in June 2019. David is a Certified Public Accountant. He received his B.S. in business administration from Northeastern University and an M.S. in taxation from Bentley University.